As kratom questions increase, many pharmacists and other health care professionals may remain unfamiliar it and the potential risks.
|Podcasts|July 19, 2022
Pharmacy Focus: Oncology Edition - A Look Ahead at the Pipeline for Melanoma
This month, we spoke with Bob Luschen, PharmD, clinical coordinator for the pharmacy department at cancer Treatment Centers of America, Atlanta.
Advertisement
This month, we spoke with Bob Luschen, PharmD, clinical coordinator for the pharmacy department at cancer Treatment Centers of America, Atlanta, to learn about pharmacists' roles in melanoma treatment and what's coming down the pipeline.
Advertisement
Related to this article
Matthew Porteus, MD, PhD, highlighted preclinical advances in automated stem cell gene editing that could improve manufacturing scalability while supporting the development of next-generation genetic medicines.
Payer requirements, prescriber habits, and operational realities ultimately determine which ICI patients receive.
Accelerated approval for patients who progressed on platinum and immunotherapy brings a new mechanism—and a familiar toxicity profile.
If approved, the combination would be the first chemotherapy-free, Bruton tyrosine kinase inhibitor–based regimen for adults with newly diagnosed mantle cell lymphoma (MCL).
Manufacturing delays, financial barriers, and complex care coordination can limit access to gene therapy, emphasizing the need for patient-centered programs and long-term follow-up.
Pharmacy Times previews enlicitide, survodutide, diet and heart failure risk, and pharmacist-led HF care ahead of the AHA Scientific Sessions in Chicago.
Experts highlighted how Diamond-Blackfan anemia illustrates the scientific, financial, and manufacturing challenges that can prevent promising gene therapies for ultra-rare diseases from reaching patients.
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Grants Priority Review to Zanubrutinib Plus Rituximab for Previously Untreated MCL
2
What Drives First-Line Immunotherapy Selection in NSCLC? Data, Payers, and Habit
3
AHA 2026: Insights on Oral PCSK9, Survodutide, and HF Care Come to Chicago
4
Frontline Immunotherapy Options in NSCLC: Are Checkpoint Inhibitors Interchangeable?
5